<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies</h1>
<div class="graphic"><div class="figure"><div class="ttl">EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="10%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>When no better explanation for the symptoms and signs exists, these classification criteria can be used.</strong></td> </tr> <tr class="divider_top"> <td class="subtitle1" rowspan="2">Variable</td> <td class="subtitle1" colspan="2">Score points</td> <td class="subtitle1" rowspan="2">Definition</td> </tr> <tr> <td class="subtitle2">Without muscle biopsy</td> <td class="subtitle2">With muscle biopsy</td> </tr> <tr> <td colspan="4"><strong>Age of onset</strong></td> </tr> <tr> <td class="indent1">Age of onset of first symptom assumed to be related to the disease ≥18 years and &lt;40 years</td> <td class="centered">1.3</td> <td class="centered">1.5</td> <td>Age ≥18 but &lt;40 years at onset for first symptom assumed to be related to the disease.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Age of onset of first symptom assumed to be related to the disease ≥40 years</td> <td class="centered">2.1</td> <td class="centered">2.2</td> <td>Age (years) at onset of first symptom assumed to be related to the disease ≥40.</td> </tr> <tr> <td colspan="4"><strong>Muscle weakness</strong></td> </tr> <tr> <td class="indent1">Objective symmetric weakness, usually progressive, of the proximal upper extremities</td> <td class="centered">0.7</td> <td class="centered">0.7</td> <td>Weakness of proximal upper extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually progressive over time.</td> </tr> <tr> <td class="indent1">Objective symmetric weakness, usually progressive, of the proximal lower extremities</td> <td class="centered">0.8</td> <td class="centered">0.5</td> <td>Weakness of proximal lower extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually progressive over time.</td> </tr> <tr> <td class="indent1">Neck flexors are relatively weaker than neck extensors</td> <td class="centered">1.9</td> <td class="centered">1.6</td> <td>Muscle grades for neck flexors are relatively lower than neck extensors as defined by manual muscle testing or other objective strength testing.</td> </tr> <tr class="divider_bottom"> <td class="indent1">In the legs, proximal muscles are relatively weaker than distal muscles</td> <td class="centered">0.9</td> <td class="centered">1.2</td> <td>Muscle grades for proximal muscles in the legs are relatively lower than distal muscles in the legs as defined by manual muscle testing or other objective strength testing.</td> </tr> <tr> <td colspan="4"><strong>Skin manifestations</strong></td> </tr> <tr> <td class="indent1">Heliotrope rash</td> <td class="centered">3.1</td> <td class="centered">3.2</td> <td>Purple, lilac-colored or erythematous patches over the eyelids or in a periorbital distribution, often associated with periorbital edema.</td> </tr> <tr> <td class="indent1">Gottron papules</td> <td class="centered">2.1</td> <td class="centered">2.7</td> <td>Erythematous to violaceous papules over the extensor surfaces of joints, which are sometimes scaly. May occur over the finger joints, elbows, knees, malleoli, and toes.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Gottron sign</td> <td class="centered">3.3</td> <td class="centered">3.7</td> <td>Erythematous to violaceous macules over the extensor surfaces of joints, which are not palpable.</td> </tr> <tr> <td colspan="4"><strong>Other clinical manifestations</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Dysphagia or esophageal dysmotility</td> <td class="centered">0.7</td> <td class="centered">0.6</td> <td>Difficulty in swallowing or objective evidence of abnormal motility of the esophagus.</td> </tr> <tr> <td colspan="4"><strong>Laboratory measurements</strong></td> </tr> <tr> <td class="indent1">Anti-Jo-1 (anti-histidyl-tRNA synthetase) autoantibody present</td> <td class="centered">3.9</td> <td class="centered">3.8</td> <td>Autoantibody testing in serum performed with standardized and validated test, showing positive result.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Elevated serum levels of creatine kinase (CK)* <strong>or</strong><br/> lactate dehydrogenase (LD)* <strong>or</strong><br/> aspartate aminotransferase (ASAT/AST/SGOT)* <strong>or</strong><br/> alanine aminotransferase (ALAT/ALT/SGPT)*</td> <td class="centered">1.3</td> <td class="centered">1.4</td> <td>The most abnormal test values during the disease course (highest absolute level of enzyme) above the relevant upper limit of normal.</td> </tr> <tr> <td colspan="4"><strong>Muscle biopsy features—presence of:</strong></td> </tr> <tr> <td class="indent1">Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibers</td> <td class="centered"> </td> <td class="centered">1.7</td> <td>Muscle biopsy reveals endomysial mononuclear cells abutting the sarcolemma of otherwise healthy, non-necrotic muscle fibers, but there is no clear invasion of the muscle fibers.</td> </tr> <tr> <td class="indent1">Perimysial and/or perivascular infiltration of mononuclear cells</td> <td class="centered"> </td> <td class="centered">1.2</td> <td>Mononuclear cells are located in the perimysium and/or located around blood vessels (in either perimysial or endomysial vessels).</td> </tr> <tr> <td class="indent1">Perifascicular atrophy</td> <td class="centered"> </td> <td class="centered">1.9</td> <td>Muscle biopsy reveals several rows of muscle fibers, which are smaller in the perifascicular region than fibers more centrally located.</td> </tr> <tr> <td class="indent1">Rimmed vacuoles</td> <td class="centered"> </td> <td class="centered">3.1</td> <td>Rimmed vacuoles are bluish by H&amp;E staining and reddish by modified Gomori trichrome stains.</td> </tr> </tbody></table></div><div class="graphic_footnotes">EULAR: European League Against Rheumatism; 
	ACR: American College of Rheumatology;  H&amp;E: hematoxylin and eosin.<br/>
	
	* Serum levels above the upper limit of normal.</div><div class="graphic_reference">Reproduced with permission from: Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76(12):1955-64. Copyright © 2017 BMJ Publishing Group Ltd.</div><div id="graphicVersion">Graphic 115665 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
